Post-earnings recap
Reported
Tue, Jan 29, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Biogen's strong EPS performance indicates solid profitability, which pleased investors and led to a 1.35% increase in the stock price. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors will be watching closely for more information in upcoming quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.99 | N/A | +2.33% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized a focus on long-term growth.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value through our innovative therapies.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—